Actively Recruiting
Use of Phenylephrine for Assessment of Mitral Regurgitation Severity
Led by Montefiore Medical Center · Updated on 2025-07-20
35
Participants Needed
1
Research Sites
286 weeks
Total Duration
On this page
Sponsors
M
Montefiore Medical Center
Lead Sponsor
B
Baylor College of Medicine
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study proposes to develop a phenylephrine protocol to be used during transesophageal echocardiography, whereby intravenous phenylephrine would be used to increase afterload with the intent to mimic the awake hemodynamic profile and variation that occurs with normal physical activity. The expectation is to see changes in severity of Mitral Regurgitation (MR) grade with increasing afterload, which in turn can provide more accurate quantification of MR severity to assist in clinical decision making.
CONDITIONS
Official Title
Use of Phenylephrine for Assessment of Mitral Regurgitation Severity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years or older with mitral regurgitation on baseline echocardiographic evaluation
- Patients scheduled to undergo transesophageal echocardiography for further evaluation of mitral regurgitation
You will not qualify if you...
- Patients not clinically eligible for transesophageal echocardiography
- Patients with contraindications to esophageal intubation
- Patients with hemodynamic instability
- Patients with acute decompensated heart failure
- Patients with un-revascularized severe coronary artery disease (triple vessel or left main disease)
- Patients with ongoing unstable angina or ongoing myocardial infarction
- Patients with significant arrhythmias including atrial fibrillation
- Patients with uncontrolled hypertension (blood pressure 64; 150/90 mmHg)
- Patients with preexisting bradycardia (heart rate < 50) and heart blocks
- Patients with severe symptomatic peripheral vascular disease
- Patients with severe pulmonary hypertension (estimated systolic pulmonary arterial pressure 64; 60 mm Hg)
- Patients at high risk for intracranial bleeding such as those with previous strokes, transient ischemic attack, or vascular malformations
- Patients with mean arterial blood pressure greater than 100 mmHg during TEE
- Patients with severe mitral regurgitation (effective regurgitant orifice area > 39 cm2) on baseline TEE evaluation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Montefiore Medical Center
New York, New York, United States, 10470
Actively Recruiting
Research Team
M
Mario Garcia, MD
CONTACT
W
Waqas Hanif, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here